Search Results

Displaying Results 1-2 of 2 "'OFG'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

Jun 07, 2026, 20:10 ET Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

that of orforglipron (OFG). In vitro studies demonstrated that ASC30 was approximately 2- to 3-fold more potent than OFG. In non-human primates (NHPs), ASC30 administered at 1.5 mg/kg stimulated statistically significant and substantially greater insulin secretion than OFG administered at 6 mg/kg.

More news about: Ascletis Pharma Inc.

Feb 05, 2026, 09:00 ET Mayfair Capital Partners™ Expands Team with Addition of Ryan Grand

Privacy Policy, please call 800.722.2289 or contact us at [email protected]. OFG-2601-45

More news about: Oxford Financial Group

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.